BioNTech SE (BNTX) Q2 2026 Earnings
As seen on the 24/7 Wall St. homepage on August 4, 2026.
Q2 2026
EPS
-$2.22
est -$2.08
-6.8%
Revenue
$106M
est $156M
-32.2%
Management cut full-year 2026 guidance to 1.6-1.9 billion euros from 2.0-2.3 billion after Germany drew down existing COVID vaccine inventory instead of ordering more. Oncology now funds the future: six pivotal trials started in the first half, with Guido Oelkers taking over as CEO by February 2027.
Mentioned: BNTX